Skip to content

Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study

Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01938677
Enrollment
67
Registered
2013-09-10
Start date
2013-04-30
Completion date
2022-12-31
Last updated
2024-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vestibular Schwannoma

Keywords

Vestibular schwannoma, Gamma knife radiosurgery, Hearing preservation

Brief summary

The effect of Gamma knife radiosurgery (GKRS) on hearing loss, in patients with vestibular schwannoma (VS) and preserved hearing is still unclear. Retrospective data indicate that the hearing is preserved in most patient years after the gamma knife treatment. Recent prospective data suggests that radiosurgery could be a hearing preserving treatment for these patients. The main objective of this study is to evaluate if GKRS can inhibit progression of hearing loss in patients with VS. Patients with preserved hearing will be offered to participate in the study and randomized ether to GKRS or initial conservative treatment for their vestibular schwannoma. They will then be followed with scheduled magnetic resonance image(MRI) and audiometry and evaluated after one, three and five years after treatment.

Interventions

RADIATIONInitial Gamma knife radiosurgery

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients newly (\<6 months) diagnosed with Vestibular schwannoma less than 20 mm in diameter. 2. Vestibular schwannoma with or without evidence of growth. 3. Patients between 18 and 80 years of age. 4. Karnofsky performance score \>70 5. Patients with vestibular schwannoma and preserved hearing according to Gardner Robertson class 1-2, and speech discrimination (SD) scores between 50-100% will participate in the hearing preservation part of the study. \-

Exclusion criteria

* 1\. Patients with Neurofibromatosis type 2 will be excluded to achieve a homogenous study population. 2\. Patients who had other treatments prior to the GKRS (usually microsurgery (MS), GKRS or external beam radiation) for their tumour will also be excluded for the same reason. 3\. Patients who are not citizens in the country where they will be followed will be excluded, to reassure the same follow up within the study population. 4\. Hearing loss due injury or to active ear disease, such as Meniere´s disease, otosclerosis or chronic otitis media. 5\. Patients with poor comprehension of the the language in the country where they are followed, such that adequate performance on speech tests, are unlikely. 6\. Claustrophobia, making MR follow up impossible without sedation. 7. Alcohol- or narcotic abuses that effect compliance to the follow up. 8. Uncontrolled neoplastic disease.

Design outcomes

Primary

MeasureTime frameDescription
The numbers of participants with preserve hearingup to five years after enrollmentBaseline audiometric investigation will be performed at time of enrollment. Patients will be followed with audiometric investigations after 1, 3 and 5 years after gamma knife or conservative treatment.Primary endpoint will be numbers of patients with preserve hearing for each treatment arm.

Secondary

MeasureTime frameDescription
Tumor control1, 2, 5 years after enrollmentMR investigation including digitalized volumetric of vestibular schwannomas will be performed

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026